Targeted Diseases

  • Home
  • Targeted Diseases

Algernon Pharmaceuticals has developed strong pre-clinical data that supports the advancement of 4 of its leading drug candidates into phase II trials in the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic pulmonary fibrosis (IPF).

NASH

Non–alcoholic Steatohepatitis
More about NASH

CKD

Chronic Kidney Disease
More about CKD

IBD

Inflammatory Bowel Disease
More about IBD

IPF

Idiopathic Pulmonary Fibrosis
More about IBD
Algernon Pharmaceuticals is a clinical stage pharmaceutical development company focused on the areas of non–alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), inflammatory bowel disease (IBD) and idiopathic Pulmonary fibrosis. (IPF)
Sign up for our News Releases
Head Office
Suite 915 – 700 West Pender Street
Vancouver, BC, Canada • V6C 1G8
© Algernon Pharmaceuticals - All Rights Reserved

Hit enter to search or ESC to close